Ulixertinib

Stocks of 10 mM PP242 (Sigma, #P0037), 25 mM Latrunculin A (Enzo, #BML-T119–0100), 10 mM Ulixertinib (MedChemExpress, #HY-15816), 50 mM LY294002 (Invitrogen, #PHZ1144), 10 mM ZSTK474 (Cell Signaling, #13213), 10 mM Y27632 (Enzo, #ALX-270–333-M001), 25 mM Latrunculin B (Enzo, #BML-T110–0001), 1 mM Jasplakinolide (Enzo, #ALX-350–275-C050) and 10 mM Rapamycin (Cayman, #13346) were prepared by dissolving the chemicals in DMSO. The stocks were diluted to the indicated final concentrations in culture medium or live cell imaging medium. The EGF stock solution was prepared by dissolving EGF (Sigma, #E9644) in 10 mM acetic acid to a final concentration of 1 mg/ml. Insulin (Sigma #I-1882) was resuspended at 10 mg/ml in sterile ddH2O containing 1% glacial acetic acid. Hydrocortisone (Sigma #H-0888) was resuspended at 1 mg/ml in 200 proof ethanol. Cholera toxin (Sigma #C-8052) was resuspended at 1 mg/ml in sterile ddH2O and stored at 4°C. All drug stocks except Cholera toxin were stored at −20°C.

Dabrafenib (GSK2118436, BRAFi), vemurafenib (PLX4032), and SCH772984 (ERKi-SCH) were purchased from SelleckChem. Ulixertinib (ERKi-Uli) was purchased from MedChem Express. Fibronectin was purchased from Sigma. For in vitro studies, drugs were dissolved in either dimethyl sulfoxide (DMSO) for Dabrafenib, vemurafenib, SCH772984, and Ulixertinib or water for Fibronectin. For in vivo studies, Dabrafenib and Ulixertinib were dissolved in 1% carboxymethylcellulose.